Don’t miss out - Get your tickets early!

Join this FREE, 60-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.

Join this FREE WEBINAR presented by Dr Rick Doblin PhD (USA), Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

Science has shown psychedelic medicines offer healing, resilience and comfort where there seemed to be none. The Food and Drug Administration has named them "breakthrough therapies" for mental health conditions that lack effective treatments. Indigenous communities have known their benefits for centuries, but legal restrictions have stripped them of their rites and remedies. With over 120 current and recent trials for psychedelic-assisted therapies we are seeing a renaissance in this field.

This webinar will answer the following questions:

Where are we now and what are the next steps to ensure these medicines become available as soon as possible?
Can psychedelics benefit those not helped by modern medicine?
Could they help political rivals find common ground and work together to build a better future?
Can their benefits be accessed equitably, without leaving vulnerable groups behind and reinforcing patterns of oppression and exploitation?
Can they revitalize the economy by creating new industries? Can they offer a model for harm reduction that could help address the opioid epidemic and other addictions?

Topic: Psychedelic Renaissance? Update on Research and Progress Around the World

Date: Wednesday 25 November 2020

Time: 12:55pm for 1:00pm start – 2:15pm (incl Q&A) (AEDT)

The presentation WILL BEGIN AT 1:00pm.

Location: Online. A link will be emailed to you with the viewing details

Don’t miss out - Get your tickets early!

More about medicinal psychedelic treatments:

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

More about the presenters

Dr Rick Doblin (USA)
BSc, Ph.D
Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner.

His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college or recently graduated.

Tania de Jong AM
LL.B (Hons), GradDipMus
Founder & Deputy Chair of Mind Medicine Australia

Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities over the past 3 decades. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global. She was appointed a Member of the Order of Australia in June 2008 and named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in 2018.

Support psychedelic research and therapy development

By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.

Please click here to make a tax-deductible donation.

Disclaimer

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.

Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.